TCT-576: Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non- Compliant Plaque to Deliver Durable Long-Term Results  by unknown
TUESDAY, NOVEMBER 8, 2011, 8:00 AM - 10:00 AM
between April 2010 and May 2011. PEVAR procedures with adjunctive ‘pre-close’ of
the common femoral arteries (CFAs) targeted for large sheath access using the ProGlide
or Prostar XL closure devices were performed using the Endologix IntuiTrak System.
All patients were followed procedurally and to 30 days for major adverse events and
access-related vascular complications.
Results: Patients presented at a mean age of 71 years with mean aneurysm sac diameter
of 5.6cm. Pre-close procedural success was 97% (37/38 patients). In one patient,
ProGlide devices failed to achieve ipsilateral CFA hemostasis, leading to bleeding
requiring transfusion and surgical vascular repair. All endovascular repairs were
successful. No mortality or major adverse events occurred. Other pre-close related
complications occurring within 30 days included pseudoaneurysm, lower extremity
ischemia, and blood transfusion.
Conclusion: PEVAR with adjunctive ‘pre-close’ techniques using the ProGlide or
Prostar XL devices is safe and feasible as applied in this multicenter experience.
Continued evaluation in a prospective, randomized trial is warranted.
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Long-term Mortality After Aortic Dissection in the Community - Results from
the Kaiser Permanente Registry of Aortic Dissections (KP-RAD)
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Background: Survival estimates of patients with aortic dissection commonly come
from tertiary care centers; such estimates may be biased by referral and selection bias.
The survival rate of unselected patients with aortic dissection in the community remains
poorly defined.
Methods: Aortic dissection cases where identified from the Kaiser Permanente-
Registry of Aortic Dissections (KP-RAD). This population-based registry was designed
to capture consecutive cases of aortic dissections occurring among the approximately
3,000,000 health plan members in Southern California. Aortic dissections were
categorized as either type A or B. The endpoint for the analysis was all-cause mortality.
The failure rate by dissection type was compared using the Kaplan-Meier method.
Results: There were 347 aortic dissection cases identified. Of these, 141 were type A
aortic dissection and 206 were type B aortic dissection. The mean age of the cohort
was 64 ± 16 years and 36% were female. The 30-day mortality for type A dissections
was 10.0% and 4.4% for type B dissections. However, at 6 months, the event rates
were similar; the mortality in the type A dissection group was 12.3% compared to
11.7% in the type B dissection group. The mortality rate by dissection type is shown
in the figure.
Conclusion: Type A aortic dissections are associated with higher 30-day mortality
compared to type B dissections. However, by 6-months the mortality rate is similar in
both groups. Very close follow-up in the first six months after aortic dissection seems
warranted.
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Background: Endovascular treatment of the superficial femoral artery (SFA) is
associated with an inflammatory response correlated with restenosis. Dexamethasone
delivered into the vessel adventitia at the treatment site may abate post-intervention
inflammation and reduce restenosis rates.
Methods: Patients with TASC II A, B, and C disease of the SFA were eligible for this
study. Following successful intervention, an adventitial micro-infusion catheter,
(Bullfrog®, Mercator MedSystems, San Leandro, Calif.), was advanced over a 0.014”
wire to the treated segment. Its micro-needle (0.9 mm long x 140 μm diameter) was
deployed into the adventitia to deliver dexamethasone (DEX, 4 mg/ml) mixed with
iodixanol contrast agent (80:20 ratio), providing fluoroscopic visualization. In total, 5
mg of DEX was infused per 5 cm of treated artery.
Results: Six patients have been enrolled in this study (mean age, 66 years). Mean
lesion length was 88 mm and included 3 TASC II As, 2 Bs, and 1 C lesion (4/6 were
chronic total occlusions). Each case resulted in complete cylindrical distribution of
DEX in the adventitia around the target artery with 100% technical success and no
adverse events, Table 1. Treatment required an average of 2.7 injections per patient.
Conclusion: Adventitial drug delivery is a feasible alternative to luminal or intimal
delivery modes. The micro-infusion catheter is a safe and efficient method to achieve
adventitial drug delivery. Further study is warranted to determine if DEX treatment of
the SFA decreases restenosis rates.
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Background: Acute type A aortic dissection still carries a 25% mortality based on
international registries, while mortality for complicated type B dissection has been
significantly reduced with the advent of thoracic endovascular aortic repair (TEVAR).
The purpose of this study was to simulate type A dissection by computational fluid
dynamics (CFD) to determine the relationship of tearing force to dissection
propagation, and to determine anatomic feasibility of TEVAR in patients with acute
type A dissection by characterizing primary intimal tears using 64-multislice
computerized tomography (MSCT).
Methods: Computational models of aortic dissection were constructed. Dissection
propagation was represented in single- and double-entry tear models. Impact of
pressure field distribution on tearing force was determined. On the clinical side,
radiology database was screened for acute type A aortic dissection on 64-slice CT
scans. Seventeen patients were reviewed for physical characteristics of intimal tears.
Potential obstacles for TEVAR were sought.
Results: On CFD, tearing force for dissections with a single entry tear was
approximately proportional to the rate of pressure rise and the second power of
dissection length. Introduction of a second tear distally along the dissection away from
the primary entry tear significantly reduced tearing force. On MSCT, ascending aorta
(29%) and sinotubular junction (29%) were the most frequent regions where intimal
tears originated. Location of intimal tears in nearly 75% of patients was inappropriate
for TEVAR, and 94% of patients did not have sufficient proximal or distal landing
zone required for secure fixation. Only one patient met all technical criteria for TEVAR
using currently available devices.
Conclusion: TEVAR for aortic dissection should ideally cover both entry and re-entry
tears to reduce risk of propagation. Location of intimal tear, aortic valve insufficiency,
and aortic diameter were major factors limiting use of TEVAR for acute type A
dissection. Available stents used to treat type B dissection do not address anatomic
constraints present in type A dissection in the majority of cases, such that new device
development would be required.
TCT-576
Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non-
Compliant Plaque to Deliver Durable Long-Term Results
Prakash Makam, Ricardo Guedes
Cardiovascular Research of Northwest Indiana, LLC, Muenster, IN
Background: Resistant fibrotic and calcified plaques are a major limitation in the
treatment of peripheral arterial disease (PAD). Balloon angioplasty typically ranges 8-
16 atms in these plaques, and subsequent dissection rates range 40-74%, with bail-out
stent rates as high as 40%. Plaque modification as a first-line endovascular therapy
alters lesion compliance to prevent dissections and the need for stent placement. We
report a single center experience utilizing the next generation orbital technology, called
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durability of plaque modification.
Methods: Patients with PAD underwent primary intervention with orbital technology
followed by low pressure balloon. Lesion compliance markers, including maximum
post-orbital balloon inflation pressures, inflation times, dissection rates and bail-out
stent rates, were recorded. 12-month reintervention rates were also tracked.
Results: 46 patients (74% male, 71 yrs) with 57 fibrotic or calcified lesions. Patient
demographics: diabetes (50%), renal disease (39.1%), CAD (67%), HTN (98%),
hyperlipidemia (94%), Rutherford 3-5. Lesion locations: CFA (9%), SFA (56%),
popliteal (19%) and tibial/peroneal (16%). Average pre-treatment stenosis was 89%.
In 84% of cases, balloon inflation was utilized to achieve a mean residual stenosis of
10.5%. Mean maximum inflation pressure was 5.3 atms for a mean of 2.3 min. 1
dissection was reported. No bail-out stenting was required. 5 patients (10.9%) returned
for re-treatment of the target lesion within the 12-month follow-up period.
Conclusion: In this study, the use of orbital technology modified lesion compliance
in resistant plaques as demonstrated by low pressure and short duration post-orbital
balloon inflations. Bail-out stenting was eliminated in this challenging patient
population, and use of orbital technology resulted in durable long-term results with a
low reintervention rate.
TCT-577
TEVAR in 2011: Worldwide Experience with a Conformable Graft. Does the
Combination of Flexibility and Radial Strength Lead to Positive Outcomes in
Thoracic Pathologies?
Zvonimir Krajcer
Cardiology, Texas Heart Institute, Houston, TX
Background: The anatomies of patients treated with TEVAR are as diverse as the
pathologies that are being treated. Increased graft flexibility and conformability may
contribute to a device’s ability to adapt to these different anatomies and pathologies.
We report the worldwide experience of the Valiant thoracic stent graft (Medtronic
Vascular, Santa Rosa, Calif) in treatment across aortic pathologies.
Methods: Three major studies encompassing multiple pathologies are included in this
analysis. VALOR II: a 160 patient prospective, nonrandomized, pivotal trial conducted
in the US for the treatment of descending Thoracic Aneurysm (TAA) or degenerative
disease, The Valiant Captivia Registry: a 100 patient post market registry conducted
in Europe for the treatment of TAA or Aortic Dissection, and the VIRTUE Registry: a
100 patient prospective European registry for the treatment of acute, sub-acute, or
chronic dissection.
Results: Thirty day mortality across all studies was 3.1-4%. The incidence of stroke
at 30 days was 2.5 – 4% while spinal cord ischemia rates were less than 2%. There
were no Type 1a endoleaks reported in the VIRTUE cohort and 1.5% incidence in the
Valiant Captivia Registry group at 30 days. The incidence of Type 1 endoleak in the
VALOR II cohort was 3% at 1 year. Across all patients, there was only 1 rupture and
1 conversion which were attributed to the same patient.
Conclusion: Early results from the VALOR II Study, the Valiant Captivia Registry,
and the VIRTUE Registry demonstrate that the Valiant thoracic stent graft with its high
conformability is effective in treating a variety of thoracic aortic pathologies including
TAA and degenerative disease, as well as, acute, sub-acute, and chronic dissection.
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Mechanical Thrombectomy in Treatment of Limb Ischemia: Interim Results of
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Background: To report registry data in which limb ischemia patients were treated with
mechanical thrombectomy.
Methods: A two-phase ongoing prospective registry of the MEDRAD Angiojet
catheter used in the treatment of acute and chronic limb ischemia was examined.
Electronic data capture case report forms were completed by site staff collecting
patient’s history, procedural information including adjunctive treatments, outcomes
and adverse events. Phase I patients were followed to 3 months post procedure while
the ongoing phase II patients will be followed for 12 months.
Results: Currently 271 patient with acute (200/271; 74%) and chronic (71/271; 26%)
limb ischemia at 42 centers have been treated (160 male and 111 female, mean age 66;
range 21 to 96 years). All patients were treated with the Angiojet catheter, with 63%
receiving lytic delivery by the AngioJet. CDT occurred in 45%. Full patency was
achieved in 82% with a statistically significant improvement in ABIs (p<0.0001). Initial
hospitalization AEs included: bleeding requiring transfusions 10/271 (4%), bypass
surgery (11/271 (4%) and amputation 9/271 (3%). Of the 80% (218/271) with 3 month
follow ups, 7/271 (3%) reported bypass surgery and another 6/271 (6%) had an
amputation. The physical and mental QOL scores improved from baseline 37% and
11%, respectively. A 93% (124/133) limb salvage rate was reported for the acute limb
ischemia patients with baseline Rutherford classifications of IIa, IIb and III.
Conclusion: Mechanical thrombectomy combined with adjunctive treatments is an
effective and safe strategy for limb ischemia.
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A New concept of Stent:the Multilayer Stent.First Human Study in Peripheral
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Michel Henry1, 2, Amira Benjelloun3, Antonios Polydorou4, Isabelle Henry5
1CABINET DE CARDIOLOGIE, Nancy, France; 2Global Research Institute,
Hyderabad, India; 3Clinique Coeur et Vaisseaux, Rabat Sale, Morocco;
4Pantaleimon General Hospital, Athens, Greece; 5Polyclinique Bois Bernard, Bois
Bernard, France
Background: Arterial aneurysms are traditionally treated surgically, but more and
more by interventional procedures using covered stents Endografts or coils with a high
technical success rate, but some problems are not solved like protection of aneurysm
rupture, endoleaks, stent thrombosis. We developed a new concept of stent, the
Multilayer stent (M.S) to treat aneurysms and try to avoid some drawbacks encountered
with endografts.
Methods: This M.S is a 3 Dimensional braided tube made of several interconnected
layers without any covering. Our earliest tests in vitro (theorical simulation,
computerized Fluid dynamics, Molecular Modelization) and in vivo tests demonstrate
that this MS reduces the velocity in the aneurismal sac up to 90% by modifying the
hemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the flow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this M.S preserves
the collateral branches allowing the possibility to cover any artery without
compromising the flow (renal, digestive arteries, supra aortic vessels …)
Results: 32 peripheral aneurysms (iliac:20, femoral:1, popliteal:4, renal:6,
mesenteric:1) were treated with the M.S, (male:25, mean age 61+/-8y) (42 stents Ø 5
to 14mm; length 40 to 100 mm) were implanted to treat these aneurysms, by femoral
approach. Technical success in all patients. No complications. All aneurysms
thrombosed with diameter reduction in some patients. 6 month to 30 month follow up
will be presented and we will discuss the time needed to achieve exclusion and the
factors influencing this exclusion. Allthe side branches remained patent.
Conclusion: A new concept of stent,is developed to treat aneurysm. It opens a new
approach to treat peripheral aneurysms avoiding most of the complications encountered
with current endovascular techniques. The results obtained seem promising. A larger
study is ongoing.
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Background: Conventional balloon angioplasty in Superficial femoral and popliteal
artery territories is associated with a high restenosis rates 12 months post-procedure.
Recent clinical data have suggested that use of DEBs may substantially reduce
restenosis. The impact of InPact Admiral(Medtronic Invatec, Roncadelle, Italy)DEB
use on provisional stenting and 12 month clinical outcomes in routine clinical practice
is described.
Methods: This prospective, observational registry enrolled patients with Rutherford
class 2, 3, or 4 femoropoliteal arterial disease with reference vessel diameter of 3 to 7
mm and lesion or occlusion length ≤15 cm. Endpoints included restenosis rate, target
lesion revascularization (TLR), and change in Rutherford class and ankle-brachial
index (ABI). Walking capacity and quality of life (QOL) were also assessed
Results: At 12 months follow up, 105 patients (114 lesions) were evaluable. Baseline
ABI was 0.56 ± 0.15. Baseline Rutherford classification was 26.7% for class 2, 64.8%
for class 3, and 7.6% for class 4. Most lesions were located in the middle and distal
superficial femoral artery (77.1%). The device was successfully deployed in all patients
and only 12.3% of lesions required stenting. The rate of TLR was 8.7% at 12 months.
QOL and functional status were substantially improved at all time points with 88% in
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